Anna Salina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anna Salina has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Aline Stalder Siebeneichler
Clinic of Pneumology, University Hospital Basel, Basel, Switzerland
1 shared publication - Andrei M. Darie
Lung Transplant Service, Alfred Hospital and Monash University, Melbourne, Australia
1 shared publication - Daiana Stolz
Clinic of Respiratory Medicine and Faculty of Medicine, University of Freiburg, Freiburg, Germany
1 shared publication - Eleni Papakonstantinou
Clinic of Pneumology, Medical Center, University of Freiburg, 79106 Freiburg im Breisgau, Germany
1 shared publication - Kathleen Jahn
Clinic of Respiratory Medicine, University Hospital Basel, Basel, Switzerland
1 shared publication - Leticia Grize
Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital Basel, Basel, Switzerland
1 shared publication
Latest Publications
- 29 June 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (1) , 2300218
Airway smooth muscle area to predict steroid responsiveness in COPD patients receiving triple therapy (HISTORIC): a randomised, placebo-controlled, double-blind, investigator-initiated trial
Background: Although inhaled corticosteroids (ICS) are highly effective in asthma, they provide significant, but modest, clinical benefit in COPD. Here, we tested the hypothesis that high bronchial airway smooth muscle cell (ASMC) area in COPD is associated with ICS responsiveness.Methods: In this investigator-initiated and -driven, double-blind, randomised, placebo-controlled trial (HISTORIC), 190 COPD patients, Global Initiative for Chronic Obstructive Lung Disease stage B–D, underwent bronchoscopy with endobronchial biopsy. Patients were divided into groups A and B, with high ASMC area (HASMC: >20% of the bronchial tissue area) and low ASMC area (LASMC: ≤20% of the bronchial tissue area), respectively, and followed a run-in period of 6 weeks on open-label triple inhaled therapy with aclidinium (ACL)/formoterol (FOR)/budesonide (BUD) (400/12/400 μg twice daily). Subsequently, patients were randomised to receive either ACL/FOR/BUD or ACL/FOR/placebo and followed for 12 months. The primary end-point of the study was the difference in post-bronchodilator forced expiratory volume in 1 s (FEV1) over 12 months between patients with LASMC and HASMC receiving or not receiving ICS.Results: In patients with LASMC, ACL/FOR/BUD did not significantly improve FEV1over 12 months, as compared to ACL/FOR/placebo (p=0.675). However, in patients with HASMC, ACL/FOR/BUD significantly improved FEV1, as compared to ACL/FOR/placebo (p=0.020). Over 12 months, the difference of FEV1change between the ACL/FOR/BUD group and the ACL/FOR/placebo group was 50.6 mL·year−1within the group of patients with LASMC and 183.0 mL·year−1within the group of patients with HASMC.Conclusion: COPD patients with ΗASMC respond better to ICS than patients with LASMC, suggesting that this type of histological analysis may predict ICS responsiveness in COPD patients receiving triple therapy.
- 29 June 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (1) , 2300218
Airway smooth muscle area to predict steroid responsiveness in COPD patients receiving triple therapy (HISTORIC): a randomised, placebo-controlled, double-blind, investigator-initiated trial
Background: Although inhaled corticosteroids (ICS) are highly effective in asthma, they provide significant, but modest, clinical benefit in COPD. Here, we tested the hypothesis that high bronchial airway smooth muscle cell (ASMC) area in COPD is associated with ICS responsiveness.Methods: In this investigator-initiated and -driven, double-blind, randomised, placebo-controlled trial (HISTORIC), 190 COPD patients, Global Initiative for Chronic Obstructive Lung Disease stage B–D, underwent bronchoscopy with endobronchial biopsy. Patients were divided into groups A and B, with high ASMC area (HASMC: >20% of the bronchial tissue area) and low ASMC area (LASMC: ≤20% of the bronchial tissue area), respectively, and followed a run-in period of 6 weeks on open-label triple inhaled therapy with aclidinium (ACL)/formoterol (FOR)/budesonide (BUD) (400/12/400 μg twice daily). Subsequently, patients were randomised to receive either ACL/FOR/BUD or ACL/FOR/placebo and followed for 12 months. The primary end-point of the study was the difference in post-bronchodilator forced expiratory volume in 1 s (FEV1) over 12 months between patients with LASMC and HASMC receiving or not receiving ICS.Results: In patients with LASMC, ACL/FOR/BUD did not significantly improve FEV1over 12 months, as compared to ACL/FOR/placebo (p=0.675). However, in patients with HASMC, ACL/FOR/BUD significantly improved FEV1, as compared to ACL/FOR/placebo (p=0.020). Over 12 months, the difference of FEV1change between the ACL/FOR/BUD group and the ACL/FOR/placebo group was 50.6 mL·year−1within the group of patients with LASMC and 183.0 mL·year−1within the group of patients with HASMC.Conclusion: COPD patients with ΗASMC respond better to ICS than patients with LASMC, suggesting that this type of histological analysis may predict ICS responsiveness in COPD patients receiving triple therapy.